TrialBlood advances2026

Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.

Richard R Furman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.